Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.41 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148965 | 1.00 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1968950 | 1.00 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17560394 | 0.98 | SLC6A1 (0.48) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL5555738 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1469604 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL20824836 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1749149 | 0.87 | — | — | |
| SCHEMBL184265 | 0.87 | — | — | |
| SCHEMBL512691 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL23778361 | 0.85 | EPHX1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372573-A | The synthesis technology of antihyperglycemic drug intermediate R-3- amino-piperadine dihydrochloride | 苏州汉德创宏生化科技有限公司 | 2019-10-25 | — | — | CN | claimed |
| EP-2410855-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LTD (IL) | 2016-06-01 | — | — | EP | claimed |
| EP-2471775-B1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO (JP) | 2013-01-23 | — | — | EP | claimed |
| EP-2471775-A1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-07-04 | — | — | EP | claimed |
| EP-2410855-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | Mapi Pharma Limited (IL) | 2012-02-01 | — | — | EP | claimed |
| EP-2269986-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | claimed |
| WO-2010109468-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA HK LIMITED (CN) | 2010-09-30 | — | — | WO | claimed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-3681877-B1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-10-16 | — | — | EP | disclosed |
| EP-4434980-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20050261352-A1 | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | SLC6A1 3601/4885SLC6A11 3891/4885TSHR 1179/4885 |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | SLC6A1 1605/4885SLC6A11 2191/4885TSHR 567/4885 |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | SLC6A1 3536/4885SLC6A11 4169/4885TSHR 3598/4885 |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | SLC6A1 2683/4885SLC6A11 2286/4885TSHR 4153/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | SLC6A1 4449/4885SLC6A11 4672/4885TSHR 2271/4885 |
| US-20050261352-A1 | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides | CHRM1, CHRM2, CYP3A43 | SLC6A1 358/4885SLC6A11 225/4885TSHR 144/4885 |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | SLC6A1 2165/4885SLC6A11 1838/4885TSHR 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.